Additional pre-clinical work suggests that phenformin mediated AMPK activation can directly inhibit the mitogen-activated protein kinase (MAPK) pathway and provide a synergistic effect in combination with BRAF/MEK inhibitors in melanoma tumors with BRAF V600E/K mutations (24). Here, MAP2K7 is linked to melanoma.